In VivoBiopharma merger and acquisition value for the first quarter of 2025 reached $38.4bn from 41 transactions, 22 of which had disclosed values. Making up almost 38% of that total was Johnson & Johnso
ScripAstraZeneca already considers China one of its most important markets and is increasing its focus there, announcing a $2.5bn research and development investment in Beijing along with three partnership
In VivoDevice Transactions Continuing the downward trend in financing over the past several quarters, the device industry collected $1.2 billion in Q2 funding, a 48% decrease from Q1's $2.3 billion total. It
HBW InsightSigning Olympic swimmer Ryan Lochte to promote Pine Bros. Softish Throat Drops in ads that play on his recent apology for his misbehavior in Brazil is a characteristically risky movefor Pine Bros. L